About Abivax SA - American Depositary Shares (ABVX)
Abivax SA is a biopharmaceutical company that focuses on the development of innovative therapeutics to treat inflammatory diseases and certain viral infections. The company is primarily engaged in research and development of its proprietary product candidates, leveraging its unique platform technologies to discover and optimize treatments. Abivax aims to address significant unmet medical needs through the advancement of its drug candidates into clinical trials, with a strong emphasis on developing solutions that improve patient outcomes and quality of life. Read More
The financial markets are abuzz with significant corporate developments as several key companies navigate pivotal moments, ranging from prestigious S&P index inclusions to critical quarterly earnings reports. Robinhood Markets (NASDAQ: HOOD) and AppLovin (NASDAQ: APP) are making headlines with their impending entry into the benchmark S&P 500 index,
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
